Original language | English (US) |
---|---|
Pages (from-to) | 293-295 |
Number of pages | 3 |
Journal | Biochemical Pharmacology |
Volume | 36 |
Issue number | 2 |
DOIs | |
State | Published - Jan 15 1987 |
Externally published | Yes |
Bibliographical note
Funding Information:Redistribution of 13HfDMI from tissues to plasma is supported by the observed decreasei n radiolabel con-centrationin mostt issueso f DMI-As-treated animalsc om-pared to control animals (Fig. 2, Table 1). Decreasesi n radiolabel concentrationw ere substantial,r anging from 51% in musclet o 77% in fat. Comparabled ecreasesw ere found in brain (74%) and heart (54%), the targeto rgans for DMI toxicity. The decreaseso bservedi n theseo rgans support the potential use of DMI-As to reverse DMI toxicity.I t mustb e emphasizedh, owever,t hat the dose of [3H]DMI used in this study was less than <O.OOlo f the toxic dose. Furthers upportf or the potentialt herapeuticu seo f DMI-As is provided by the rapid time courseo f redistribution of radiolabel. In humans, DMI toxicity from overdose progressesr apidly and most deathso ccur within hours of drugi ngestion[ 4].I f D&II-As is to be of usei n treatingD MI toxicity, antagonismo f toxicity must be correspondingly rapid. In the current study, nearly half of the maximum increasein plasmar adiolabelc oncentrationo ccurredw ithin 2 min of DMI-As administrationT. his observations uggests that the pharmacokinetice ffect of DMI-As on [3H]DMI distributioni s prompt enought o warrantf urther studya s a therapeutica gent.